Alphaversus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTAPESIN and 213Bi-AMBA versus177Lu-DOTAPESIN) - Wild, D; Frischknecht, M; Zhang, H (Cancer Res, 2011)
et al.